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bstract
Increasing experimental evidence indicates that short polybasic peptides are able to translocate across the membrane of living cells. However,
hese peptides, often derived from viruses and insects, may induce unspecific effects that could mask the action of their cargoes. Here, we show that
panel of lysine and/or arginine-rich peptides, derived from human proteins involved in cell signalling pathways leading to inflammation, possess
he intrinsic ability to cross intact cellular membranes. These peptides are also capable of carrying a biologically active cargo. One of these peptides,
ncompassing the cell permeable sequence of the Toll-receptor 4 (TLR4) adaptor protein (TIRAP) and modified to carry a dominant-negative
omain of the same TIRAP protein, selectively inhibited the production of pro-inflammatory cytokines upon LPS challenge, in in vitro, ex vivo and
n vivo experiments. Docking studies indicated that this inhibition might be mediated by the disruption of the recruitment of downstream effector
olecules. These results show for the first time the potential of using for therapy cell permeable peptides derived from human proteins involved
n disease.
2007 Elsevier B.V.
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. Introduction
The identification and characterisation of cell permeable pep-
ides, or protein transduction domains (PTDs), has generated
onsiderable interest, as they offer the opportunity to transport
argo polypeptides across cell membranes for a variety of appli-
ations. To date, PTDs have been used to deliver a number
f molecules in vivo and in vitro, including enzymes, sig-
alling molecules and apoptotic proteins, with the aim to dissect
ntracellular signalling pathways, regulate gene transcription,
anipulate inflammatory responses and inhibit tumour progres-
ion (Lindsay, 2002; Christiaens et al., 2004; Wadia and Dowdy,
005; Gondeau et al., 2005; Bernatchez et al., 2005; Toshchakov
t al., 2005).
∗ Corresponding author. Tel.: +44 207 594 1651; fax: +44 207 584 2056.
E-mail address: w.low@imperial.ac.uk (W. Low).
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Among the inflammatory responses, those due to activation
f Toll-like receptors (TLRs) have been intensively studied.
number of blocking peptides have been employed in vitro
o delineate signal transduction pathways downstream of
LR4 and TLR2 (Horng et al., 2001; Toshchakov et al.,
005). Exposure of TLR4 to microbial components such as
ipopolysaccharide (LPS) from Gram-negative bacteria triggers
n intracellular signal cascade leading to the secretion of
ro-inflammatory mediators followed by an immune response.
LRs share homologous cytoplasmic domains that are termed
he Toll-Interleukin 1 receptor (TIR) homology domains. TIR
omain-containing adaptors such as MyD88 (Medzhitov et
l., 1998) and the TIR domain-containing adaptor protein
TIRAP) (Horng et al., 2001), also termed MyD88 adaptor-
ike (MAL) (Fitzgerald et al., 2001), couple TLR4 receptor
ctivation to downstream signalling. These molecules are
otential targets for therapeutic intervention and therefore
t is anticipated that antagonists of TLR4 signal transduc-
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ion might be able to modulate harmful pro-inflammatory
esponses such as those observed in septic shock or severe
epsis.
TIRAP was first identified by Horng et al. (2001) and its
ole in TLR4 signalling was investigated using a cell-permeable
locking peptide, encompassing a translocating sequence of
he antennapedia homeodomain (Joliot et al., 1991; Derossi
t al., 1994) covalently linked to a TIRAP dominant negative
omain. This domain, termed the BB loop (Xu et al., 2000),
s highly conserved among TIR domains. Horng et al. (2001)
peculated that this peptide might act as a specific inhibitor of
IRAP by competing with TIRAP for interaction with TLR4.
owever, conflicting results obtained from studies carried out
ith macrophages from TIRAP knock-out mice (Yamamoto et
l., 2002; Horng et al., 2002) have raised the possibility that
nhibition with the TIRAP blocking-peptides may have been
aused by the unspecific binding of the antennapedia transduc-
ion domain.
In addition to antennapedia, other functionally and struc-
urally unrelated peptides, including TAT from human
mmunodeficiency virus (Green and Loewenstein, 1988; Frankel
nd Pabo, 1988) and VP22 from herpes simplex virus (Elliott
nd O’Hare, 1997), have been shown to cross intact cellular
embranes. However, recent evidence suggests that, as in the
ase of antennapedia mentioned above, when used as carri-
rs, these transducing peptides can cause unwanted effects that
ay either counteract the action of their cargoes or unspecifi-
ally enhance it (Fotin-Mleczek et al., 2005). Interestingly, in
ll cases, the ability to translocate maps to short amino acid
equences lacking in apparent sequence homology but charac-
erised by a high content of basic amino acids such as arginine
nd lysine (Bogoyevitch et al., 2002; Vives, 2003). Substitu-
ion of arginine or lysine residues in TAT and antennapedia
ith alanines was shown to result in a marked decrease in
eptide internalisation (Wender et al., 2000; Gratton et al.,
003).
In order to avoid the unspecific effects produced by ‘exoge-
ous’ carriers such as Antenapedia, VP22 and TAT, we have
nvestigated the cell-permeability properties of lysine and
rginine-rich domains of human proteins which are known
o be intimately involved in cell signalling pathways inherent
o inflammation. A series of synthetic peptides was tested in
itro and shown to possess the intrinsic ability to move across
ellular membranes. One of these peptides, derived from the
IRAP protein, was then fused to a cargo encompassing a dom-
nant negative domain of the same protein. This fusion peptide,
amed TBX2, selectively delayed the kinetics of p38 activa-
ion following exposure to LPS in a fashion similar to that
bserved in cells from TIRAP knock-out mice. Furthermore,
BX2 selectively inhibited pro-inflammatory cytokine produc-
ion upon LPS challenge in vivo. Docking analysis suggested
hat TBX2 may disrupt the heterotrimeric complex forma-
ion between TLR4, MyD88 and TIRAP by binding TLR4
t different non-overlapping sites. These results provide the
ationale for the development of highly specific peptides for
nterfering with signal transduction and may pave the way to
he development of novel tools for the treatment of human
C
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iseases such as sepsis syndrome and chronic inflammatory
iseases.
. Materials and methods
.1. Database analysis
The EMBOSS (http://www.emboss.org) program fuzzpro
as used to search SWISS-PROT for the following motifs
K/R]-X-[K/R]-[K/R]-[K/R], [K/R]-[K/R]-X-[K/R]-[K/R] and
K/R]-[K/R]-[K/R]-X-[K/R], where K is lysine, R is arginine
nd X is any amino acid. The resulting lists were parsed in Perl
o produce a non-redundant list of entries.
.2. Model building and computational methods
Initially, TBX2 secondary structure prediction was obtained
sing the PSIPRED v2.4 (Mcguffin et al., 2000) web-interfaced
acilities [http://bioinf.cs.ucl.ac.uk/psipred]. The 3D model
tructure was constructed using the protein building module
f Sybyl (version 7.0), and checked for atom and/or bond
ype correctness using the Sketch module of Sybyl. Hydrogen
toms were added using standard Sybyl geometries and mini-
ized with Powell algorithm with a gradient of 1 kcal/(mol A˚)
nd 1000 cycles to remove potential bad contacts. The peptide
as been refined using RAPPER (Depristo et al., 2005). The
nal 3D structure present in the complex has been minimized
sing the Amber force field present in the compute module of
ybyl7.0.
.3. Homology modelling
Sequence homologues were retrieved using PSI-BLAST
Altschul et al., 1997). Swiss-pdb (Guex and Peitsch, 1997)
PHModels2.0 server were used to generate 3D models
f each protein. The models of the proteins have been
btained according to the PDB crystal structure coordinates
f 1077 pdb (Tao et al., 2002). Evaluation of obtained struc-
ure values have been performed with the software WHAT
F http://biotech.embl-heidelberg.de:8400/) and RAMAPAGE
http://www-cryst.bioc.cam.ac.uk/rampage) and have been
ompared to the reference PDB. Hydrogen atoms were added
o the models using standard Sybyl geometries, and minimized
ith the Powell algorithm with a gradient of 0.5 kcal/(mol A˚)
nd 1000 cycles to remove potential bad contacts. Mod-
ls have been analysed using the protein preparation tool in
ybyl7.0.
.4. Protein–protein, protein–peptide docking and HINT
oftware
The models of complexes between TLR4 and the adap-
or proteins, Tirap and Myd88, were constructed using the
lusPro Algorithm (Comeau et al., 2004). The HINT soft-
are (Kellogg et al., 1991) was used to predict protein–ligand,
rotein–protein and macrocycle–macrocycle associations by
ssessing hydrophobic, hydrogen bonds and polar interactions
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etween the two interacting macromolecules. Protein–protein
nd protein–peptide complexes were minimized using the amber
orce field present is sybyl7.0.
.5. Peptide synthesis
Peptides were produced by solid phase step-wise synthesis
SPSS) using the Fmoc N-terminal protection strategy. All pep-
ides were made with C terminal carboxamide functionality.
hain assembly was performed on Applied Biosystems 433 or
ioneer automated synthesisers.
N terminal biotinylation was performed on the synthesiser
hrough activation of the biotin carboxylic acid in the same way
s for amino acids.
4-Chloro-7-nitrobenzofurazan (NBD) was attached to the
eptide N terminal amino group using a manual method. This
as achieved with high efficiency by incubating the N terminal
eprotected peptide-resin with a five fold excess of NBD with
wo fold excess diisopropylethylamine (DIEA) in dimethylfor-
aide (DMF) for 18 h with gentle mixing.
All peptide products were analysed by reverse phase HPLC
r CZE as appropriate. Purification was performed by reverse
hase HPLC. Confirmation of peptide molecular weight was
erformed by MALDI. All the peptides were solubilized in PBS.
Peptide sequences: TAT, GRKKRRQRRRPPQ; TATAla,
RKKAAQAAAPPQ; IRAK1, CLHRRAKRRPPMTQV-
ER; TLR4, GRHIFWRRLRKALLDGKSWNPE; TIRAP,
KMADWFRQTLLKKPKKRPNSPEST;TIRAPAla, GKMA-
WFRQTLLAAPAAAPNSPEST; BX2, LQLRDATPGGA-
VS; TBX2, GKMADWFRQTLLKKPKKRPNSPESTLQLR-
ATPGGAIVS; Antp-TIRAP, RQIKIWFQNRRMKWKKL-
LRDAAPGGAIVS; PU.l, GSKKKIRLYQFLLDLLRSGDM-
DS; ICE, QLLRKKRRIFIHSVGAGT.
.6. Peptide internalisation assays
HeLa or RAW 264.7 cells were cultured at 37 ◦C, 10% CO2,
n Dulbecco’s modified Eagle’s medium (DMEM) (Invitro-
en), containing 10% foetal calf serum (FCS, Harlan), 100 U/ml
enicillin and 100g/ml streptomycin. Quantification of inter-
alisation of NBD-labelled peptides was carried out according
o the procedure described by Drin et al. (2001). Briefly, cells
ere seeded in six-well plates (5 × 105 cells/well) and treated
ith 0–160M of peptide for 2 h at 37 ◦C. Cells were washed
wice in PBS, harvested using a solution of Versene (1:500)
Invitrogen) and re-suspended in 0.5 ml (final volume) of ice-
old PBS. Cells were analysed by flow cytometry using a
ecton Dickinson FACS Scan instrument and the geometric
ean of fluorescence intensity was considered to represent the
mount of cell-associated peptide. Following flow cytometry,
l of freshly prepared dithionite stock solution (1 M Na2S2O4
n 1 M Tris–HCl (pH 10)) was added to cells maintained at
◦C for 5 min and analysed again with flow cytometry to
easure residual fluorescence. Fluorescence from cells treated
ith dithionite only was subtracted from the fluorescence of
ell-associated or internalised peptides to infer background
alues.
d
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.7. Immunoblot analysis
RAW 264.7 cells were treated with PBS or 160M TBX2
eptide for 2 h at 37 ◦C, 10% CO2, in DMEM, containing 10%
oetal calf serum and antibiotics. Cells were stimulated with
0 ng/ml of LPS and samples were collected after 0, 10, 20
nd 45 min. Cells were lysed in sample buffer and separated
y 12% SDS-PAGE and transferred onto nitrocellulose mem-
rane (Amersham). Membranes were blocked for 1 h in 5% dry
ilk in PBS and 0.1% Tween 20 at RT, and then probed with
n anti-ACTIVE p38 (Promega) antibody for 1 h. After wash-
ng with PBS and 0.1% Tween 20, the primary antibody was
etected using a goat anti-rabbit horseradish peroxidase conju-
ate (1:2000, Jackson Labs). To control that different samples
ere loaded in equal amounts, the membranes were also incu-
ated with the mouse monoclonal anti-pan phospho-tyrosine
ntibody 4G10 (a gift from X. Montano) followed by a goat-
nti mouse Horse Radish Peroxidase (HRPO) antibody (1:2000,
ackson Labs). Detection of HRPO antibodies was performed
sing an enhanced chemiluminescence detection system (ECL,
mersham).
.8. Cytokine analysis
RAW 264.7 cells were treated with different concentrations
f peptides for 2 h at 37 ◦C, 10% CO2, in DMEM, contain-
ng 10% foetal calf serum and antibiotics and then stimulated
ith 10 ng/ml LPS (E. coli 055:B5, Sigma), 25g/ml Poly I:C
InvivoGen) or 1g/ml R848 (InvivoGen). Supernatants were
ollected 22 h post agonist challenge and IL-6 levels quanti-
ed by ELISA, according to the manufacturer’s instructions
R&D Systems). Primary human macrophages, isolated from
single donors buffy coats, were treated with different con-
entrations of the TBX2 or the BX2 peptides for 2 h at 37 ◦C,
0% CO2, in DMEM, containing 10% autologous serum and
ntibiotics and then stimulated with 1 ng/ml LPS for 18 h.
he levels of TNF- present in the supernatants were quan-
ified by ELISA, according to the manufacturer’s instructions
Pharmingen).
.9. Animal experiments
Groups of five female mice (strain C3H/HeN) were injected
ntravenously (I.V.) with a single dose of TBX2 peptide (2, 4
r 6 mg per mouse) or PBS only. After 45 min, the mice were
hallenged with 10g of LPS injected i.v. 90 min later, the mice
ere anaesthetised and blood collected by cardiac puncture. The
evels of TNF- in the serum were quantified by ELISA accord-
ng to the manufacturer’s instructions (Pharmingen). All animal
xperiments were performed in compliance with institutionally
pproved protocols at Imperial College.
.10. Cell viabilityCellTiter-Glo Luminescent Assay (Promega) was utilised to
etermine viability of RAW 264.7 cells following treatment with
eptides, according to the manufacturer’s instructions.
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.11. Statistical analysis
Standard deviation (S.D.) and standard error of the mean
S.E.M.) were calculated using Microsoft Excel. Statistical anal-
sis was carried out using Student’s t-test.
. Results
.1. Peptides derived from human proteins and containing
ationic motifs are capable of crossing the membrane of
iving cells
In addition to the well characterised polybasic PTDs (Frankel
nd Pabo, 1988; Green and Loewenstein, 1988; Joliot et al.,
991; Derossi et al., 1994; Elliott and O’Hare, 1997), a nuclear
ocalisation signal (NLS) derived from SV40 and containing
our lysines and one arginine (Peitz et al., 2002), and a peptide
erived from the prion protein (PrP) containing the sequence
KRPK (Lundberg et al., 2002), were shown to be able to
ranslocate across cell membranes. On the basis of these obser-
ations, we formulated the hypothesis that short stretches of
ationic amino acids could confer cell permeable properties
o certain human peptides. We therefore screened the human
roteome databases for proteins containing motifs encompass-
ng five charged residues of either arginine or lysine allowing
or a single mismatch at positions 2, 3 or 4. A search in the
wiss-Prot protein database (http://us.expasy.org/sprot/) identi-
ed a large number of non-redundant, non-hypothetical human
roteins known to function as kinases, transcription factors,
roto-oncogenes, receptors and DNA repair enzymes. To test
ur hypothesis, focusing on cell signalling proteins linked to
mmune responses and inflammation, five peptides derived
rom proteins linked to pathological conditions and/or to cel-
ular signalling pathways were synthesised and their ability to
unction as PTDs assessed. These included the human Toll-
nterleukin 1 receptor (TIR) domain-containing adapter protein
TIRAP) (Horng et al., 2001) (alternatively known as MyD88-
dapter-like (Mal); Fitzgerald et al., 2001), the Interleukin-1
eceptor-associated kinase 1 (IRAK1), the toll-like receptor 4
TLR4), the transcription factor PU.1 (PU.1) and the caspase-1
nhibitor Iceberg (ICE). The peptides were designed to encom-
ass the cationic motif flanked by endogenous sequences of
p to 20 amino acids, and linked to a 7-nitrobenz-2-oxo-l,3-
iazol-4-yl (NBD) at the amino terminal end (Drin et al., 2001).
his fluorophore is irreversibly quenched by the addition of cell
mpermeable sodium dithionite, thus enabling discrimination of
eptides merely bound to the cells from truly intracellular ones.
oreover, its use allows a direct measurement of the amount
f internalised peptides in live cells, therefore avoiding arte-
acts due to fixation (Langeduk et al., 2004; Drin et al., 2003;
hristiaens et al., 2004). Cultured epithelial HeLa cells were
ncubated with NBD-labelled peptides at three concentrations
ither in the presence or in the absence of sodium dithionite. Cul-
ured cells were also treated with a TAT peptide and a mutated,
ATAla in which five arginine residues were substituted by ala-
ines, to serve as positive and negative controls, respectively.
eptide internalisation was deduced by quantifying cell fluores-
r
o
J
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ence by FACS analysis. All tested peptides gave fluorescence
alues similar or higher than TAT when added to HeLa cells in
he presence of sodium dithionite, whereas very little fluores-
ence was observed with TATAla at all concentrations tested.
he fluorescent signal increased in a peptide concentration-
ependent manner (Fig. 1A), in agreement with previous reports
n TAT and Antp (Drin et al., 2003; Derossi et al., 1996;
ehlke et al., 1997; Hallbrink et al., 2001). The specificity of the
ptake was investigated by incubating both murine macrophage-
erived RAW 264.7 and HeLa cells either with the NBD-labelled
IRAP peptide, or with a mutated version in which the basic
esidues forming the cationic motif were replaced with ala-
ines (TIRAPAla) (Fig. 1B). Cells treated with NBD-TIRAPAla
ere substantially less fluorescent than those treated with the
riginal TIRAP peptide, indicating that the disruption of the
ationic motif abolished the ability of the peptide to cross the cell
embrane.
.2. The human-derived cell permeable peptides can carry
biologically active cargo
To assess the biochemical and biological activity of peptides
ontaining putative PTDs in vitro and in vivo, we combined in
synthetic peptide the functional cell permeable sequence of
IRAP with a dominant negative domain from the same pro-
ein. This peptide, named TBX2, therefore encompassed the
equence of TIRAP shown to have cell permeable properties
n HeLa and RAW 264.7 cells (Fig. 1B) (amino-acids 19–43)
nd a region of the BOX2 domain (Fitzgerald et al., 2001)
amino-acids 118–131), also known as the BB-loop (Xu et al.,
000). This region is highly conserved among TIR domains
nd forms the core of a dominant negative domain by compet-
ng the interaction of endogenous TIRAP with the cytoplasmic
ail of Toll receptor 4 (TLR4) (Horng et al., 2001). To inves-
igate whether the TIRAP dominant negative domain linked
o the cell permeable sequence present in TBX2 was able
o inhibit TLR4 activity, RAW 264.7 cells were treated with
PS and increasing concentrations of TBX2. The effect of
BX2 on the TIRAP-dependent activation of p38, a member
f the mitogen activated protein kinase family, was assessed by
mmunoblot analysis using an antibody that selectively recog-
ises the phosphorylated, active form of p38. As shown in Fig. 2,
BX2 caused a temporal shift in the appearance of the peak
f phosphorylated p38 in RAW 264.7 cells upon LPS treat-
ent. These results are in agreement with the observed kinetics
f p38 phosphorylation in isolated peritoneal macrophages
Yamamoto et al., 2002) and bone marrow-derived macrophages
Horng et al., 2002) from TIRAP knock-out mice in response
o LPS. Notably, the treatment with the Antp-TIRAP peptide,
ncompassing the PTD of Antp from D. melanogaster and
he BB loop sequence derived from the mouse TIRAP gene
Horng et al., 2001), resulted instead in complete inhibition
f p38 phosphorylation in response to LPS (Fig. 2). Previous
eports had shown that the BB-loop, when fused to the PTD
f Antennapedia, could inhibit the activation of MAP kinase
NK and NF-B in RAW 264.7 cells upon LPS challenge
Horng et al., 2001). While TBX2 reproduced the p38 activa-
W. Low et al. / Journal of Biotechnology 129 (2007) 555–564 559
Fig. 1. Internalisation of peptides. (A) Mean fluorescence values of NBD-treated HeLa cells measured after the addition of sodium dithionite quencher. Back-
ground values of cell treated with sodium dithionite only were subtracted. Cells (5 × l05 cells ml−1) were incubated with 10 (black bar), 40 (grey bar) and
160M (white bar) of each of the NBD labelled peptides TAT (GRKKRRQRRRPPQ), TATAla (GRKKAAQAAAPPQ), TIRAP (GKMADWFRQTLLKKP-
KKRPNSPEST), IRAKI (CLHRRAKRRPPMTQVYER), TLR4 (GRHIFWRRLRKALLDGKSWNPE), PU.1 (GSKKKIRLYQFLLDLLRSGDMKDS) and ICE
(QLLRKKRRIFIHSVGAGT) for 2 h. The results are the average of three independent experiments. Error bars represent standard error of the mean (n = 3). (B)
Structure to function analysis of the cell permeable motif found in TIRAP. Increasing concentrations of the NBD-labelled peptides TIRAP (dark grey bar), TIRAPAla
(GKMADWFRQTLLAAPAAAPNSPEST) (light grey bars), TAT (black bars) and TAT Ala (white bars) were incubated with HeLa and RAW 264.7 cells. The amount
of internalised peptide was determined by adding sodium dithionite quencher as described. The results are the average of three independent experiments. Error bars
represent standard error of the mean (n = 3).
560 W. Low et al. / Journal of Biotechn
Fig. 2. Kinetics of p38 phosphorylation in LPS treated RAW 264.7 macrophages
upon addition of TBX2. Cells were pre-incubated with PBS, 40M of
Antp-TIRAP (RQIKIWFQNRRMKWKKLQLRDAAPGGAIVS) or 160M
of TBX2 (GKMADWFRQTLLKKPKKRPNSPESTLQLRDATPGGAIVS) for
2 h and then stimulated with 10 ng/ml LPS for the indicated periods of time.
Cell lysates were separated on 12% SDS-polyacrylamide gel and blotted onto
nitrocellulose membrane. Activation of p38 was detected using a specific anti-
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formation between TLR4, MyD88 and TIRAP
To obtain a better insight into the nature of TBX2 inhibition
of p38 phosphorylation in response to LPS, we have modelled
Fig. 3. Activity of the TBX2 peptide. (A) TBX2 activity on IL-6 secre-
tion of LPS stimulated RAW 264.7 cells. RAW cells were pre-incubated
with increasing concentrations of TBX2 (GKMADWFRQTLLKKPKKRPN-
SPESTLQLRDATPGGAIVS) for 2 h and then challenged with 10 ng/ml LPS,
or 25g/ml Poly I:C or 1g/ml R848. Supernatants were collected after 18 hhospho-p38 antibody. For each experiment, the amount of cell lysate loaded
as assessed using an anti-pan phospo-tyrosine antibody. Immunoblot analysis
s representative of four independent experiments.
ion pattern observed in TIRAP knock-out mice, Antp-TIRAP
id not.
.3. Suppression of cytokine production following
ransduction of the TBX2 peptide in vitro, ex vivo and in vivo
TIRAP-deficient mice show an impaired production of the
nflammatory cytokine IL-6 in response to LPS (Yamamoto et
l., 2002; Horng et al., 2002). Consistently, incubation of RAW
64.7 cells with TBX2 resulted in dose-dependent inhibition of
L-6 production in response to LPS (Fig. 3A).
To assess the specificity of TBX2-mediated inhibition on the
LR4-TIRAP signalling pathway, RAW 264.7 cells were treated
ith either Poly (I:C) (a ligand of TLR3) or the synthetic com-
ound R-848 (a ligand of TLR7) (Fig. 3A). In either case, TBX2
id not inhibit IL-6 secretion. Furthermore, no significant reduc-
ion in cellular viability was observed following treatment with
ncreasing concentrations of TBX2 over an incubation period of
p to 18 h (Fig. 3B).
We also assessed the ability of TBX2 to inhibit the production
f TNF-, a key mediator of chronic inflammatory diseases, in
reshly isolated human macrophages. Our results indicated that
t a 50M concentration of TBX2, TNF- production from
uman macrophages was reduced by 50% in response to LPS
Fig. 4A). A 14 amino-acid peptide, BX2, encompassing only
he TIRAP dominant negative sequence (Horng et al., 2001)
nd lacking the cell permeable domain, was used as control.
s expected, primary human macrophages exposed to LPS pro-
uced similar levels of TNF- either in the presence or absence
f the BX2 peptide (Fig. 4A).
To determine whether TBX2 had the ability to suppress the
xpression of inflammatory cytokine genes in vivo, a single dose
f the peptide was administered intravenously to mice 45 min
rior to challenge with LPS. The levels of TNF-, measured in
LISA on whole mice blood, were significantly reduced (over
0%) in mice treated with 2 mg of the TBX2 peptide when com-
ared with control mice (Fig. 4B). A low level of IL-10 secretion
as observed which did not differ significantly from animals
reated with LPS only to animals treated with LPS and TBX2
not shown).
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.4. TBX2 might interfer with the heterotrimeric complexnd IL-6 levels quantified by ELISA. Results show one experiment carried out in
riplicates representative of four independent experiments. Error bars represent
tandard error of the mean. NT: non-treated. (B) Cell viability assessed after
ncubation with TBX2. RAW 264.7 cells (l × 104 cells ml−1) were distributed
n 96-well plates and incubated for 2 (black bar), 4 (grey bar), 8 (white bars) and
8 h (grey dotted bars) with 10, 40 and 160M TBX2.
W. Low et al. / Journal of Biotechnology 129 (2007) 555–564 561
Fig. 4. Activity of the TBX2 peptide ex vivo and in vivo. (A) TBX2 activity
on TNF- production of LPS stimulated primary human macrophages. Pri-
mary human macrophages (see Section 2) were pre- treated with increasing
concentrations of either TBX2 (GKMADWFRQTLLKKPKKRPNSPESTLQL-
RDATPGGAIVS) (light grey bars) or BX2 (LQLRDATPGGAIVS) (white bars)
for 2 h and then challenged with 1 ng/ml LPS for 20 h. TNF- production of non-
challenged and non-treated cells is shown (NT). TNF- levels in the supernatants
were quantified by ELISA. Results are the average of triplicates and representa-
tive of two independent experiments. Error bars represent standard error of the
mean. (B) TBX2 activity on TNF- response of LPS treated mice. Groups of
five mice were injected intravenously (i.v.) with a single dose of TBX2 peptide
(2, 4 or 6 mg per mouse) or PBS only. After 45 min, the mice were challenged
with 10g of LPS injected i.v. 90 min later, the mice were anaesthetised and
blood collected by cardiac puncture. TNF- levels in the blood were determined
by ELISA. Results are representative of two independent experiments. Levels
of TNF- measured on non-challenged and PBS-treated mice were subtracted
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Fig. 5. Molecular modelling and prediction of protein–protein interaction. TLR4
(yellow), TIRAP (purple), MyD88 (red) and TBX2 (green) are shown in ribbon
representation. Conserved prolines of TLR4, MyD88 and TIRAP are shown in
ball and stick. Non-overlapping binding sites for TIRAP and MyD88 on TLR4
and the hypothetical interactions between TBX2 and TLR4 are shown. The
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4. Discussionrom TNF- values obtained from peptide treated mice. Error bars represents
tandard error of the mean n = 5. *p < 0.05, **p < 0.01.
he TIR domains of TLR4, MyD88 and TIRAP proteins. The
IRAP and MyD88 adaptor proteins were docked onto the
LR4 using Cluspro (Comeau et al., 2004). Protein–protein
omplexes (TLR4-TIRAP and TLR4-MyD88) were superim-
osed to visualize the potential ternary complex associations.
he models obtained were evaluated using the available biolog-
cal information and post-processed using the HINT software
Kellogg et al., 1991). This software predicts protein–ligand,
rotein–protein and macrocycle–macrocycle associations by
ssessing hydrophobic, hydrogen bonds and polar interac-
ions between the two interacting macromolecules. Our results
uggest that TIRAP and MyD88 bind to TLR4 in two non-
verlapping binding sites (Fig. 5). In this model, TIRAP is
redicted to associate through its BB-loop to TLR4, whereas tBX2 associates via the BB loop with TLR4 on the TIRAP binding site and
ia its amino terminus ( helix) projected towards the region of TLR4 that is
redicted to bind MyD88.
yD88 is predicted to interact with the region enclosing the
LR4 BB-loop. The P714H mutation on TLR4 has been shown
o disrupt MyD88/TLR4 complex formation (Poltorak et al.,
998) suggesting that this residue could be involved in the bind-
ng of Myd88. This is consistent with our model in which the
B-loop of TLR4 is directed towards MyD88. A correspond-
ng proline residue is also found in the BB-loops of TIRAP and
yD88. Mutation of this proline (P125H) to histidine on the
IRAP protein was proposed (Horng et al., 2001) to disrupt
IRAP-TLR4 association. Accordingly, in our TLR4-TIRAP
nteraction model, mutation of this proline (P125H) to histi-
ine could result in hydrophobic clashes. In addition, Dunne
t al. (2003) showed that the MyD88 P200 mutation has no
ffect on TLR4-MyD88 association. Again, this is consistent
ith our model in which the BB-loop of MyD88 is projected on
he opposite side of TLR4.
We then considered this ternary complex model as a basis to
etermine whether TBX2 could occupy crucial sites involved
n protein–protein interaction with TLR4. Thus, we performed
eptide–protein docking (TBX2-TLR4) analysis using TBX2
s ligand and TLR4, as receptor. The most likely TBX2-TLR4
inding complex was selected using the HINT software (Kellogg
t al., 1991), available biological information and our own
esults. In our model, TBX2 could associate through its amino
nd carboxyl terminus with TLR4 potentially hindering MyD88
nd TIRAP binding to TLR4 (Fig. 5).The efficient and transient intracellular delivery of pep-
ides and polypeptides, collectively named PTDs, allows for
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eversible regulation of biological processes. As proof of
rinciple, it has been shown that PTDs can serve several uses in
herapy. A peptide encompassing NFAT (nuclear factor of acti-
ated T cells) inhibitor linked to the cell-permeable sequence
rg10 was used as an immunosuppressive agent, to overcome
he undesired toxic effects of calcineurin inhibitors in transplant
herapy, enabling successful allogeneic islet transplantation in
ice (Noguchi et al., 2004). More recently, a c-Jun N-terminal
inase 1 (JNK1) inhibitory peptide covalently linked at its
terminus to a 10-amino-acid carrier peptide derived from
he HIV-TAT sequence, has been shown to improve insulin
esistance and glucose tolerance in diabetic mice (Kaneto et al.,
004). In this report, we show that synthetic peptides derived
rom human proteins of medical interest and containing cationic
otifs have the intrinsic ability to translocate across intact
xtracellular membranes. Similarly to known transduction
omains such as TAT, VP22 and Antp, the selected peptides
how different extents of cell permeable properties, combined
ith the ability to function as cargo carriers. In agreement
ith previous published data, such translocation properties
re strongly dependent on arginine and lysine residues (Mi et
l., 2000; Park et al., 2002; Mai et al., 2002; Noguchi et al.,
005). Importantly, all peptides chosen for the analysis were
apable of entering cells, indicating that although the available
ollection of five functional transduction peptides identified
ere is not large enough to rigorously prove our hypothesis,
he presence of stretches of arginine and lysine residues is a
ood marker to predict, before experimental verification, which
equence may function as a PTD. It should to be noted that
he choice of the flanking sequences may also affect individual
ctivity.
In addition, to demonstrate intracellular delivery of biologi-
ally active polypeptides and to disclose the general therapeutic
nd technological applications of human peptides containing
ndogenous cell-permeable motifs, we used an inhibitory
eptide entirely derived from the TIRAP adaptor molecule
o interfere with the functionality of the TLR4 pathway, as
easured by a delay in p38 activation and by the inhibition of
ytokine production in LPS challenged cells and mice. Notably,
hile TBX2 closely reproduced the p38 activation pattern
bserved in TIRAP knock-out mice, the Antp-TIRAP peptide
id not, causing a total inhibition of p38 activation. Although,
e cannot rule out that the single amino acid substitution (T-
A) on the TIRAP portion of TBX2 and Antp-TIRAP peptides
ay contribute to p38 activation, our findings seem to indicate
hat the presence of the PTD derived from the Drosophila Antp
omeodomain induces unwanted biological effects, confirming
hat had been previously suggested (Toshchakov et al., 2005;
abroe et al., 2003; Vogel and Fenton, 2003; O’Neill, 2003).
he toxicity and immunogenicity of several well known PTDs
as been discussed in detail (Trehin R and Mrkle HP 2004).
nterestingly, a recent study demonstrated that translocating
eptides such as Antp, TAT and nona-arginine (R9) can
ll induce effects that antagonize or enhance the effects of
he cargo being delivered (Fotin-Mleczek et al., 2005). Our
esults, confirming those obtained with TIRAP knock-out
ice, indicate that endogenous translocating peptides such as
Cology 129 (2007) 555–564
BX2 exert a specific function, avoiding unwanted effects and
oxicity.
The observation that a fraction of human proteins may
ontain putative PTDs raises the intriguing possibility that cer-
ain proteins may possess the ability to passively translocate
hrough cell membranes, as shown for the human homeopro-
ein HOXB4 (Amsellem et al., 2003) and the BETA2/NeuroD
rotein (Noguchi et al., 2005). Such a notion may also pro-
ide a theoretical framework for understanding pathological
ffects associated with necrosis (as opposed to apoptosis) that
ommonly occur in tumours, degenerative diseases and chronic
nflammatory conditions where cell permeable proteins released
y damaged cells could exert an epigenetic pathological effect
n the neighbouring ones.
In conclusion, the identification of cell permeable peptides
riginating from human proteins linked to pathological con-
itions, offers therapeutical opportunities without the need to
se exogenous, often deleterious, PTD sequences to facilitate
ellular uptake. This would have the advantage of minimize
rotein structure artefacts and unwanted biological effects due
o the insertion of foreign sequences. These proteins, either in
ecombinant forms or as synthetic peptides encompassing rel-
vant sequences, may be utilized to regulate protein–protein
r protein–DNA interactions, to transiently correct or down
egulate abnormal gene function, to interfere with signalling
athways, cell proliferation and to restore genetic defects, there-
ore facilitating the exploitation of PTD technology in therapy
nd basic research.
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